Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

The Teleflex Manta large bore vascular closure device #TCT2021

News | Vascular Closure Devices

Plug-based Vascular Closure Following TAVR Offers Shorter Hemostasis Time Than Suture-based Devices

November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies ...

November 09, 2021

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

Sponsored Content

As medical advancements continue to push the boundaries of what is possible in the field of structural heart interventions, the importance of enterprise imaging has become increasingly evident.

Blog | Enterprise Imaging

BLOG: The Power of Enterprise Imaging in Structural Heart Procedures

As medical advancements continue to push the boundaries of what is possible in the field of structural heart ...

August 10, 2023

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

The FDA cleared the world's first photon-counting computed tomography (CT) scanner, the Siemens Naeotom Alpha, in late September. This new technology will likely change the future direction of CT. Biosense Webster also announced the first cases using its Heliostar radiofrequency balloon ablation catheter were completed in September. Both were among the top stories in October.

Feature | By Dave Fornell, DAIC Editor

November 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

November 01, 2021

Videos | Structural Heart

VIDEO: Abbott Structural Heart CMO Shares Views on Future of Valve Interventions

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

October 15, 2021

$Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.$

News | Computed Tomography (CT)

Cardiac CTA Parameters Predict Post-TAVR Mortality

October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...

October 14, 2021

Videos | Structural Heart

VIDEO: How to Perform a Transcaval TAVR Procedure

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...

October 14, 2021

The Baylis VersaCross RF transseptal crossing catheter is designed to puncture the septum without a needle to allow access to the left side of the heart for mitral valve and left atrial appendage occlusion procedures. Boston Scientific to Acquire Baylis Medical for $1.75 billion.

News | Cath Lab

Boston Scientific to Acquire Baylis Medical To Expand EP and Structural Heart Portfolios

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

October 06, 2021

Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.

Feature | BY Dave Fornell, DAIC Editor

October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

October 06, 2021

The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.

News | Structural Heart Occluders

FDA Clears Abbott Amplatzer Talisman PFO Occluder

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

October 04, 2021

Videos | Stem Cell Therapies

VIDEO: Engineered Heart Tissue Aids Research With a Heart in a Dish System

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

October 04, 2021

Videos | Structural Heart

VIDEO: Roles of the Melody and Harmony Transcatheter Pulmonary Valves in Congenital Heart Disease

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

September 28, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021